financetom
Business
financetom
/
Business
/
Why CureVac (CVAC) Stock Is Rising
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why CureVac (CVAC) Stock Is Rising
Jan 6, 2025 8:42 AM

Shares of CureVac BV are trading higher by 13.5% to $4.10 during Monday’s session following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

The surge in healthcare visits, driven by higher cases of seasonal influenza, COVID-19 and RSV, has renewed interest in vaccine and therapeutic manufacturers during Monday’s trading session.

CureVac ( CVAC ), a biotechnology company specializing in mRNA technology, is seen as a key player in developing next-generation vaccines. The company is advancing its mRNA platform to address not only COVID-19 but also other respiratory viruses like RSV and influenza.

CureVac's ( CVAC ) pipeline includes partnerships and clinical trials targeting these illnesses, potentially making the company well-positioned to benefit from heightened demand for respiratory virus treatments.

Read Also: Uber CFO Says Stock Undervalued, Initiates $1.5 Billion Accelerated Stock Buyback

How To Buy CVAC Stock

By now you're likely curious about how to participate in the market for CureVac ( CVAC ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the case of CureVac ( CVAC ), which is trading at $4.07 as of publishing time, $100 would buy you 24.57 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, CVAC has a 52-week high of $5.28 and a 52-week low of $2.22.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Data Safety Review Board Issues Positive Safety Recommendation For BriaCell's Phase 3 Study
Mar 11, 2026
08:13 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that the Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. The ongoing pivotal Phase 3 study is being conducted...
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday an independent data safety monitoring board has recommended for the fifth time continuation of a phase 3 study of its Bria-IMT plus an immune checkpoint inhibitor to treat metastatic breast cancer patients after reviewing safety data. The company said the board, which neets quarterly in accordance...
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Pfizer Says Braftovi Drug Combination Showed 'Significant' Improvement in Colorectal Cancer Trial
Mar 11, 2026
08:14 AM EST, 02/17/2026 (MT Newswires) -- Pfizer ( PFE ) on Tuesday reported positive results from a trial evaluating Braftovi in combination with cetuximab and Folfiri in patients with previously untreated metastatic colorectal cancer. The regimen showed a statistically significant and clinically meaningful improvement in progression-free survival, a key secondary endpoint, Pfizer ( PFE ) said. Overall survival, a...
Palo Alto Networks Announces Intent to Acquire Koi to Secure the Agentic Endpoint
Palo Alto Networks Announces Intent to Acquire Koi to Secure the Agentic Endpoint
Mar 11, 2026
Eliminates the AI security gap by establishing Agentic Endpoint Security as the next frontier of enterprise risk reduction SANTA CLARA, Calif., Feb. 17, 2026 /PRNewswire/ -- As AI transforms workforce productivity, it has created a dangerous, unmanaged attack surface on every endpoint. These AI agents and tools—the Agentic Endpoint—operate with deep access to sensitive data, unrestricted permissions, and the ability...
Copyright 2023-2026 - www.financetom.com All Rights Reserved